rphra
live
S&P 5007,359.9-0.08%
NASDAQ29,220.06-0.43%
DOW51,848.9+0.35%
VIX18.63-4.41%
US10Y4.40-1.98%
EUR/USD1.1361-1.26%
GOLD4,014.5-6.65%
WTI69.62-7.44%
BTC60,676-5.84%
S&P 5007,359.9-0.08%
NASDAQ29,220.06-0.43%
DOW51,848.9+0.35%
VIX18.63-4.41%
US10Y4.40-1.98%
EUR/USD1.1361-1.26%
GOLD4,014.5-6.65%
WTI69.62-7.44%
BTC60,676-5.84%

SNY

Sanofi
HealthcareDrug Manufacturers - GeneralFRUSDPeers →Country macro →
$41.33
+0.09%LiveJun 24, 2026
AI Brief
Market cap
$99.37B
52w range
40.89 – 52.68
P / E
EPS
Volume
7.35M
Revenue · FY

Explain this page

Arphra AI
Next report
upcoming

No forward estimate on file.

Beat streak
0
consecutive EPS beats
Avg surprise
trailing 0q
EPS · actual vs estimate
· earnings_history
actualestimate

No earnings history on file.

Forward consensus

No forward annual estimates on file.

Revenue · actual vs estimate ($B)

No revenue estimate history on file.

Reports tracked
0
Beat rate
0 beats · 0 misses (last 12)
Next report
Last report

Earnings call transcripts

DB24
PeriodDateWordsExcerpt
FY2025 Q4Jan 29, 20269,476Thomas Larsen: Hello, everyone, this Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q4 and Full Year 2025 Conference Call for investors and analysts. As usual, you can find slides on sanoRead →
FY2025 Q3Oct 24, 20259,723Thomas Larsen: Hello everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q3 2025 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Read →
FY2025 Q2Jul 31, 202510,336Thomas Kudsk Larsen: Hello, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q2 2025 conference call for investors and analysts. As usual, you can find the slides on sanofRead →
FY2025 Q1Apr 24, 202510,421Thomas Guslatin: Hello, everyone. This is Thomas Guslatin from the Sanofi IR team. Welcome to the Q1 2025 Conference Call for investors and analysts. As usual, you can find the slides on sanofi.com. PRead →
FY2024 Q4Jan 30, 202511,497Thomas Larsen: Welcome to the Q4 and Full Year 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual fRead →
FY2024 Q3Oct 25, 202411,477Thomas Kudsk: Welcome to the Q3 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com. Please turn to slide number three. Here we have the usual forward-lookRead →
FY2024 Q2Jul 25, 20249,393Thomas Kudsk: This is Thomas Kudsk Larsen with the IR team. Welcome to the Q2 2024 Conference Call for investors and analyst. As usual, you can find the slides on sanofi.com. Please turn to slide 3. HRead →
FY2024 Q1Apr 25, 202412,457Paul Hudson: Welcome to the Q1 2024 conference call. You can find the slides of this call on the sanofi.com Investors Page. I'd like to remind you that the information presented in this call contains Read →
FY2023 Q4Feb 01, 20249,922Eva Schaefer-Jansen: Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's Fourth Quarter and Full Year 2023 Results, followed by a Q&A session. As usuRead →
FY2023 Q3Oct 27, 202311,684Eva Schaefer-Jansen: [starts abruptly] You have joined the meeting as an attendee and will be muted throughout the meeting. This meeting is being recorded. 2023 results followed by a Q&A session. As uRead →
FY2023 Q2Jul 28, 202312,135Eva Schaefer-Jansen: Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's Second Quarter 2023 Results followed by Q&A session. As usual, you can find Read →
FY2023 Q1Apr 27, 202313,487Eva Schaefer-Jansen: Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's first quarter 2023 results followed by a Q&A session. As usual, you can findRead →
FY2022 Q4Feb 03, 202312,371Eva Schaefer-Jansen: [Call Starts Abruptly] find the slides to this earnings call on the Investors page of our website at sanofi.com. Moving to slide 3, I would like to remind you that information preRead →
FY2022 Q3Oct 28, 202212,475Eva Schaefer-Jansen: Good morning, good afternoon, and good evening to everyone. Thank you for joining us to review Sanofi’s 2022 third quarter results, followed by a Q&A session. As usual, you can fiRead →
FY2022 Q2Jul 28, 202212,431Eva Schaefer-Jansen: Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's 2022 Second Quarter Results followed by a Q&A session. As usual, you can finRead →
FY2022 Q1Apr 28, 202212,492Eva Schaefer-Jansen: Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's 2022 first quarter results followed by a Q&A session. As usual, you can findRead →
FY2021 Q4Feb 04, 202213,560Eva Schaefer-Jansen: Good morning, good afternoon, and good evening to everyone. Thank you for joining us to review Sanofi’s 2021 Fourth Quarter and Full Year Results followed by a Q&A session. As usuRead →
FY2021 Q3Oct 28, 202113,035Operator: Welcome to the Sanofi's Third Quarter 2021 earnings call. I would now like to turn the call over to Eva Schaefer-Jansen, Head of Sanofi Investor Relations. Please go-ahead Eva. Eva Schaefer Read →
FY2021 Q2Jul 29, 202112,798Eva Schaefer-Jansen: [Technical Difficulty] followed by a Q&A session. As usual, you can find the slides to this earnings call on the Investors page of our website at sanofi.com. Moving to Slide 2. I Read →
FY2021 Q1Apr 29, 20218,853Operator: [Starts Abruptly] Sanofi's First Quarter 2021 Earnings Call. I would now like to turn the call over to Eva Schaefer-Jansen, Head of Sanofi Investor Relations. Please go ahead, Eva. Eva SchaeRead →
FY2020 Q4Feb 05, 202127,078Operator: This meeting is being recorded. Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi Fourth Quarter 2020 Earnings Call and Virtual Capital Markets Day. We have planned for Read →
FY2020 Q3Oct 29, 202014,572Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi Investor Call on the Q3 2020 earnings. I would now like to turn the call over to Eva Schaefer-Jansen from Sanofi InvestRead →
FY2020 Q2Jul 29, 202012,560Operator: Ladies and gentlemen, thank you for standing by. Welcome to Sanofi’s investor call on the Q2 2020 earnings. I would now like to turn the call over to Eva Schaefer-Jansen from Sanofi InvestorRead →
FY2020 Q1Apr 24, 202013,702Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi's First Quarter 2020 Earnings Conference Call. I would now like to turn the call over to Felix Lauscher, from Sanofi InRead →
Click Read → for the full transcript with keyword cloud and on-demand AI analyst summary.

Earnings surprises · history

DB · earnings_surprises100% beat2
Period endEstimate EPSActual EPSSurprise %Outcome
Apr 23, 2026$1.06$1.10+3.77%Beat
Jan 29, 2026$0.84$0.89+5.95%Beat

Earnings history

DateEPS · estEPS · actualSurpriseRevenue · estRevenue · actualResult
No earnings history available.

Analyst estimates · annual

PeriodEPS · avgRevenue · avg# Analysts
No analyst estimates returned.

Analyst estimates · quarterly

PeriodEPS · avgRevenue · avg# Analysts
No analyst estimates returned.